CL2020000439A1 - Sales de un compuesto y sus formas cristalinas. - Google Patents
Sales de un compuesto y sus formas cristalinas.Info
- Publication number
- CL2020000439A1 CL2020000439A1 CL2020000439A CL2020000439A CL2020000439A1 CL 2020000439 A1 CL2020000439 A1 CL 2020000439A1 CL 2020000439 A CL2020000439 A CL 2020000439A CL 2020000439 A CL2020000439 A CL 2020000439A CL 2020000439 A1 CL2020000439 A1 CL 2020000439A1
- Authority
- CL
- Chile
- Prior art keywords
- same
- crystalline forms
- compound
- salts
- pirazin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
LA PRESENTE INVENCIÓN PERTENECE AL CAMPO FARMACÉUTICO Y PROPORCIONA LAS SALES FARMACÉUTICAMENTE ACEPTABLES DEL COMPUESTO (S)-7-(4-(1-(METIL SULFONIL)PIPERIDIN-4-IL)FENIL)-N- (MORFOLIN-2- ILMETIL)PIRIDO[3,4-B]PIRAZIN-5-AMINA Y LAS FORMAS CRISTALINAS DE LOS MISMOS, LOS SOLVATOS Y LAS FORMAS CRISTALINAS DE LOS MISMOS, LAS COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS MISMOS, ASÍ COMO LOS MÉTODOS DE PREPARACIÓN DE LOS MISMOS Y EL USO DE LOS MISMOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710723169.3A CN109422741A (zh) | 2017-08-22 | 2017-08-22 | 化合物的盐及其晶型 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000439A1 true CL2020000439A1 (es) | 2020-08-07 |
Family
ID=65439343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000439A CL2020000439A1 (es) | 2017-08-22 | 2020-02-21 | Sales de un compuesto y sus formas cristalinas. |
Country Status (18)
Country | Link |
---|---|
US (2) | US11396507B2 (es) |
EP (1) | EP3672972A4 (es) |
JP (1) | JP7162964B2 (es) |
KR (1) | KR102650181B1 (es) |
CN (4) | CN109422741A (es) |
AU (1) | AU2018320010B2 (es) |
BR (1) | BR112020003617A2 (es) |
CA (1) | CA3072525A1 (es) |
CL (1) | CL2020000439A1 (es) |
EA (1) | EA202090532A1 (es) |
IL (1) | IL272835A (es) |
MX (1) | MX2020002015A (es) |
PH (1) | PH12020500366A1 (es) |
SG (1) | SG11202001301RA (es) |
TW (1) | TWI816690B (es) |
UA (1) | UA125942C2 (es) |
WO (1) | WO2019037737A1 (es) |
ZA (1) | ZA202001029B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114835682B (zh) * | 2022-06-17 | 2024-04-26 | 华东理工常熟研究院有限公司 | 一种吡虫啉的盐及其制备方法与用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012167423A1 (en) * | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
CN105732596B (zh) * | 2012-11-19 | 2019-05-28 | 齐鲁制药有限公司 | N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法 |
-
2017
- 2017-08-22 CN CN201710723169.3A patent/CN109422741A/zh active Pending
-
2018
- 2018-08-22 MX MX2020002015A patent/MX2020002015A/es unknown
- 2018-08-22 CN CN201880052524.1A patent/CN111094284A/zh active Pending
- 2018-08-22 EA EA202090532A patent/EA202090532A1/ru unknown
- 2018-08-22 CA CA3072525A patent/CA3072525A1/en active Pending
- 2018-08-22 SG SG11202001301RA patent/SG11202001301RA/en unknown
- 2018-08-22 JP JP2020511530A patent/JP7162964B2/ja active Active
- 2018-08-22 EP EP18848142.8A patent/EP3672972A4/en active Pending
- 2018-08-22 TW TW107129312A patent/TWI816690B/zh active
- 2018-08-22 KR KR1020207007272A patent/KR102650181B1/ko active IP Right Grant
- 2018-08-22 AU AU2018320010A patent/AU2018320010B2/en active Active
- 2018-08-22 UA UAA202001775A patent/UA125942C2/uk unknown
- 2018-08-22 CN CN202111634327.0A patent/CN114044776A/zh active Pending
- 2018-08-22 CN CN202111609042.1A patent/CN114369093A/zh active Pending
- 2018-08-22 BR BR112020003617-0A patent/BR112020003617A2/pt unknown
- 2018-08-22 US US16/641,054 patent/US11396507B2/en active Active
- 2018-08-22 WO PCT/CN2018/101699 patent/WO2019037737A1/en unknown
-
2020
- 2020-02-18 ZA ZA2020/01029A patent/ZA202001029B/en unknown
- 2020-02-21 CL CL2020000439A patent/CL2020000439A1/es unknown
- 2020-02-21 PH PH12020500366A patent/PH12020500366A1/en unknown
- 2020-02-21 IL IL272835A patent/IL272835A/en unknown
-
2022
- 2022-06-21 US US17/844,901 patent/US20220389012A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020002015A (es) | 2020-07-20 |
CN114044776A (zh) | 2022-02-15 |
WO2019037737A1 (en) | 2019-02-28 |
JP7162964B2 (ja) | 2022-10-31 |
JP2020532510A (ja) | 2020-11-12 |
EA202090532A1 (ru) | 2021-02-11 |
CA3072525A1 (en) | 2019-02-28 |
IL272835A (en) | 2020-04-30 |
KR102650181B1 (ko) | 2024-03-21 |
PH12020500366A1 (en) | 2021-01-11 |
AU2018320010A1 (en) | 2020-02-27 |
TWI816690B (zh) | 2023-10-01 |
EP3672972A4 (en) | 2021-03-24 |
US11396507B2 (en) | 2022-07-26 |
CN111094284A (zh) | 2020-05-01 |
KR20200044020A (ko) | 2020-04-28 |
CN114369093A (zh) | 2022-04-19 |
TW201912642A (zh) | 2019-04-01 |
BR112020003617A2 (pt) | 2020-09-01 |
US20210047318A1 (en) | 2021-02-18 |
AU2018320010B2 (en) | 2022-09-15 |
SG11202001301RA (en) | 2020-03-30 |
UA125942C2 (uk) | 2022-07-13 |
CN109422741A (zh) | 2019-03-05 |
EP3672972A1 (en) | 2020-07-01 |
ZA202001029B (en) | 2022-07-27 |
US20220389012A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
CL2018002803A1 (es) | Antagonistas de c5ar solubles | |
UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
UY36152A (es) | Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo | |
UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
PE20151427A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
ECSP14013215A (es) | Compuestos novedosos | |
GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
UY37160A (es) | COMPUESTOS DERIVADOS DE PIRROLIDINA CON ACTIVIDAD ANTAGONISTA DE INTEGRINA avß6 | |
ECSP19051352A (es) | Inhibidores selectivos de jak1 | |
CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
ECSP16074478A (es) | Compuestos novedosos | |
DOP2017000209A (es) | Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
UY38759A (es) | Tienilhidroxiisoxazolinas y derivados de las mismas | |
CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. | |
ECSP18056196A (es) | Derivados de indano |